[Bevacizumab (Avastin)]

Tatsu Shimoyama1

  • 1Dept. of Chemotherapy, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital.

Insights

Vascular endothelial growth factor (VEGF) drives tumor growth and spread. Bevacizumab, an antibody targeting VEGF, combined with chemotherapy, shows antitumor activity and was approved for colorectal cancer in Japan.

Area of Science:

  • Oncology
  • Molecular Biology
  • Angiogenesis Research

Context:

  • Vascular endothelial growth factor (VEGF) is crucial for tumor angiogenesis, growth, and metastasis.
  • Elevated VEGF levels in solid tumors correlate with poor clinical outcomes.
  • Targeting VEGF is a key strategy in cancer therapy development.

Purpose:

  • To investigate the efficacy and safety of bevacizumab, a monoclonal antibody targeting VEGF.
  • To evaluate bevacizumab in combination with conventional chemotherapy for cancer treatment.

Summary:

  • Bevacizumab is a recombinant humanized monoclonal antibody that inhibits VEGF.
  • Clinical studies demonstrate antitumor activity when bevacizumab is administered with chemotherapy.
  • The treatment exhibits acceptable toxicity profiles in various cancer types.

Impact:

  • Bevacizumab offers a targeted approach to inhibit tumor angiogenesis and progression.
  • Its approval for unresectable colorectal cancer in Japan (April 2007) signifies clinical utility.
  • This highlights the therapeutic potential of anti-VEGF agents in oncology.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...